[Pseudotumoral osseous change of the sternum during chronic leukemia in an adult].

N. Monetti,G. Coletta

Abstract:

What problem does this paper attempt to address?

Technology of deep brain stimulation: current status and future directions

Joachim K. Krauss,Nir Lipsman,Tipu Aziz,Alexandre Boutet,Peter Brown,Jin Woo Chang,Benjamin Davidson,Warren M. Grill,Marwan I. Hariz,Andreas Horn,Michael Schulder,Antonios Mammis,Peter A. Tass,Jens Volkmann,Andres M. Lozano

DOI: https://doi.org/10.1038/s41582-020-00426-z

IF: 38.1

2020-11-26

Nature Reviews Neurology

Abstract:Deep brain stimulation (DBS) is a neurosurgical procedure that allows targeted circuit-based neuromodulation. DBS is a standard of care in Parkinson disease, essential tremor and dystonia, and is also under active investigation for other conditions linked to pathological circuitry, including major depressive disorder and Alzheimer disease. Modern DBS systems, borrowed from the cardiac field, consist of an intracranial electrode, an extension wire and a pulse generator, and have evolved slowly over the past two decades. Advances in engineering and imaging along with an improved understanding of brain disorders are poised to reshape how DBS is viewed and delivered to patients. Breakthroughs in electrode and battery designs, stimulation paradigms, closed-loop and on-demand stimulation, and sensing technologies are expected to enhance the efficacy and tolerability of DBS. In this Review, we provide a comprehensive overview of the technical development of DBS, from its origins to its future. Understanding the evolution of DBS technology helps put the currently available systems in perspective and allows us to predict the next major technological advances and hurdles in the field.

clinical neurology
Ketoconazole Inhibits the Growth and Development of Ichthyophonus sp. (Mesomycetozoa) In Vitro

F. Hontoria,Ma Angeles González,A. Sitjà-Bobadilla,O. Palenzuela,P. Álvarez-Pellitero

DOI: https://doi.org/10.1111/j.1550-7408.2009.00427.x

2009-09-01

Journal of Eukaryotic Microbiology

Abstract:ABSTRACT. We determined the in vitro effect of the azol‐derivative antifungal ketoconazole (KZ) on the morphology, growth, and development of teleost fish parasite Ichthyophonus sp. The KZ was delivered to culture medium using liposomes (L) or a lipid emulsion (E) at five different doses (i.e. 5, 50, 100, 200, and 400 μg/ml) for both L and E formulations. Controls consisted of Eagle's minimum essential medium (MEM) supplemented with 10% foetal bovine serum (MEM‐10) alone (C‐MEM) or containing amounts of L or E equivalent to those used in the KZ100 and KZ400 treatments (i.e. 100L, 400L, 100E, and 400E, respectively). Morphological alterations, such as a decrease in the number of dividing spores and nuclei, and condensation or even destruction of the cytoplasm, were observed using light and electron microscopy in the MEM‐cultured organisms receiving KZ formulations, especially with KZ400L preparations, at both 7‐ and 14‐d postinoculation. The KZ treatments also demonstrated a statistically significant inhibition of Ichthyophonus growth in MEM. These treatments also had an inhibitory effect on subsequent Ichthyophonus germination in Earle's fish saline agar (EFSA) medium, which was more evident for L formulations when the organism was treated for 7 d and for E formulations at 14 d. Our results endorse the potential use of KZ for the treatment for ichthyophonosis and provide support to proceed to in vivo assays.
Deep Brain Stimulation Initiative: Toward Innovative Technology, New Disease Indications, And Approaches To Current And Future Clinical Challenges In Neuromodulation Therapy

Yanan Sui,Ye Tian,Wai Kin Daniel Ko,Zhiyan Wang,Fumin Jia,Andreas Horn,Dirk De Ridder,Ki Sueng Choi,Ausaf A. Bari,Shouyan Wang,Clement Hamani,Kenneth B. Baker,Andre G. Machado,Tipu Z. Aziz,Erich Talamoni Fonoff,Andrea A. Kühn,Hagai Bergman,Terence Sanger,Hesheng Liu,Suzanne N. Haber,Luming Li

DOI: https://doi.org/10.3389/fneur.2020.597451

IF: 3.4

2021-01-01

Frontiers in Neurology

Abstract:Deep brain stimulation (DBS) is one of the most important clinical therapies for neurological disorders. DBS also has great potential to become a great tool for clinical neuroscience research. Recently, the National Engineering Laboratory for Neuromodulation at Tsinghua University held an international Deep Brain Stimulation Initiative workshop to discuss the cutting-edge technological achievements and clinical applications of DBS. We specifically addressed new clinical approaches and challenges in DBS for movement disorders (Parkinson's disease and dystonia), clinical application toward neurorehabilitation for stroke, and the progress and challenges toward DBS for neuropsychiatric disorders. This review highlighted key developments in (1) neuroimaging, with advancements in 3-Tesla magnetic resonance imaging DBS compatibility for exploration of brain network mechanisms; (2) novel DBS recording capabilities for uncovering disease pathophysiology; and (3) overcoming global healthcare burdens with online-based DBS programming technology for connecting patient communities. The successful event marks a milestone for global collaborative opportunities in clinical development of neuromodulation to treat major neurological disorders.
Current and future directions of deep brain stimulation for neurological and psychiatric disorders

Darrin J Lee,Christopher S Lozano,Robert F Dallapiazza,Andres M Lozano

DOI: https://doi.org/10.3171/2019.4.JNS181761

2019-08-01

Abstract:Deep brain stimulation (DBS) has evolved considerably over the past 4 decades. Although it has primarily been used to treat movement disorders such as Parkinson's disease, essential tremor, and dystonia, recently it has been approved to treat obsessive-compulsive disorder and epilepsy. Novel potential indications in both neurological and psychiatric disorders are undergoing active study. There have been significant advances in DBS technology, including preoperative and intraoperative imaging, surgical approaches and techniques, and device improvements. In addition to providing significant clinical benefits and improving quality of life, DBS has also increased the understanding of human electrophysiology and network interactions. Despite the value of DBS, future developments should be aimed at developing less invasive techniques and attaining not just symptom improvement but curative disease modification.
Current Practice and the Future of Deep Brain Stimulation Therapy in Parkinson's Disease

Leonardo Almeida,Wissam Deeb,Chauncey Spears,Enrico Opri,Rene Molina,Daniel Martinez-Ramirez,Aysegul Gunduz,Christopher W Hess,Michael S Okun

DOI: https://doi.org/10.1055/s-0037-1601893

Abstract:Deep brain stimulation (DBS) is an effective therapy for Parkinson's disease patients experiencing motor fluctuations, medication-resistant tremor, and/or dyskinesia. Currently, the subthalamic nucleus and the globus pallidus internus are the two most widely used targets, with individual advantages and disadvantages influencing patient selection. Potential DBS patients are selected using the few existing guidelines and the available DBS literature, and many centers employ an interdisciplinary team review of the individual's risk-benefit profile. Programmed settings vary based on institution- or physician-specific protocols designed to maximize benefits and limit adverse effects. Expectations should be realistic and clearly defined during the evaluation process, and each bothersome symptom should be addressed in the context of building the risk-benefit profile. Current DBS research is focused on improved symptom control, the development of newer technologies, and the improved efficiency of stimulation delivery. Techniques deliver stimulation in a more personalized way, and methods of adaptive DBS such as closed-loop approaches are already on the horizon.
Advances in Understanding The Mechanisms of Deep Brain Stimulation

Feng Zhou-Yan,Guo Zhe-Shan,Wang Zhao-Xiang

DOI: https://doi.org/10.16476/j.pibb.2018.0126

2018-01-01

PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS

Abstract:Deep brain stimulation (DBS) has been applied widely in clinic to treat movement disorders such as Parkinson's disease. It also shows great prospects in the treatments of intractable epilepsy, refractory obsessive-compulsive disorder, and other diseases of the central nervous system in brain. Over the past three decades, the mechanisms of DBS have emerged gradually based on multiple lines of evidence in clinical applications, in animal experiments, and in simulations of computational models. Important advances in DBS mechanisms have been achieved although final conclusions are still under debate. This review analyzes and summarizes the development of DBS theories from electrophysiological perspectives: from the original theory of inhibitions or excitations to the recent prevalent theory of modulations; from focusing on neuronal activity locally at stimulation sites to discovering the decoupling of somatic and axonal responses, and further to discovering the intermittent depolarization block of axons induced by high frequency stimulations, together with de-synchronous activity presumably caused by axonal activity in population neurons in the projection brain regions. The series of advances indicate that DBS has complex mechanisms in modulating the neuronal networks. Understanding the mechanisms of DBS has significance for improving DBS therapies, for developing new stimulation modes, and for extending its clinical applications.
Deep Brain Stimulation Programming 2.0: Future Perspectives for Target Identification and Adaptive Closed Loop Stimulation

Franz Hell,Carla Palleis,Jan H. Mehrkens,Thomas Koeglsperger,Kai Bötzel

DOI: https://doi.org/10.3389/fneur.2019.00314

IF: 3.4

2019-04-03

Frontiers in Neurology

Abstract:Deep brain stimulation has developed into an established treatment for movement disorders and is being actively investigated for numerous other neurological as well as psychiatric disorders. An accurate electrode placement in the target area and the effective programming of DBS devices are considered the most important factors for the individual outcome. Recent research in humans highlights the relevance of widespread networks connected to specific DBS targets. Improving the targeting of anatomical and functional networks involved in the generation of pathological neural activity will improve the clinical DBS effect and limit side-effects. Here, we offer a comprehensive overview over the latest research on target structures and targeting strategies in DBS. In addition, we provide a detailed synopsis of novel technologies that will support DBS programming and parameter selection in the future, with a particular focus on closed-loop stimulation and associated biofeedback signals.

neurosciences,clinical neurology
Deep Brain Stimulation beyond the Clinic: Navigating the Future of Parkinson’s and Alzheimer’s Disease Therapy

Ali Chaari,Kevin Zhai,Pradipta Paul,Anns Mahboob,Alexandra Kammen,Degiri Kalana Lasanga Senevirathne,Darrin J. Lee,Mohammad S Yousef

DOI: https://doi.org/10.3390/cells12111478

IF: 6

2023-05-25

Cells

Abstract:Deep brain stimulation (DBS) is a surgical procedure that uses electrical neuromodulation to target specific regions of the brain, showing potential in the treatment of neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). Despite similarities in disease pathology, DBS is currently only approved for use in PD patients, with limited literature on its effectiveness in AD. While DBS has shown promise in ameliorating brain circuits in PD, further research is needed to determine the optimal parameters for DBS and address any potential side effects. This review emphasizes the need for foundational and clinical research on DBS in different brain regions to treat AD and recommends the development of a classification system for adverse effects. Furthermore, this review suggests the use of either a low-frequency system (LFS) or high-frequency system (HFS) depending on the specific symptoms of the patient for both PD and AD.

Medicine
The mechanisms of action of deep brain stimulation and ideas for the future development

Kaviraja Udupa,Robert Chen

DOI: https://doi.org/10.1016/j.pneurobio.2015.08.001

IF: 10.885

2015-10-01

Progress in Neurobiology

Abstract:Deep brain stimulation (DBS) has been used as a treatment of movement disorders such as Parkinson's disease, dystonia, and essential tremor for over twenty years, and is a promising treatment for depression and epilepsy. However, the exact mechanisms of action of DBS are still uncertain, although different theories have emerged. This review summarizes the current understanding in this field. Different modalities used to investigate DBS such as electrophysiological, imaging and biochemical studies have revealed different mechanisms of DBS. The mechanisms may also be different depending on the structure targeted, the disease condition or the animal model employed. DBS may inhibit the target neuronal networks but activate the efferent axons. It may suppress pathological rhythms or impose new rhythms associated with beneficial effects, and involves neuronal networks with widespread connections. Different neurotransmitter systems such as dopamine and GABA upregulation are involved in the effects of DBS. There are also technical advances to prolong the battery life and specific targeting based on new electrode designs with multiple contacts which have the ability to steer the current toward a specific direction. There is ongoing work in closed loop or adaptive DBS using neural oscillations to provide the feedback signals. These oscillations need to be better characterized in a wide variety of clinical settings in future studies. Individualization of DBS parameters based on neural oscillations may optimize the clinical benefits of DBS.

neurosciences
Collagen binding alpha2beta1 and alpha1beta1 integrins play contrasting roles in regulation of Ets-1 expression in human liver myofibroblasts.

Iya Y Znoyko,M. Trojanowska,A. Reuben

IF: 3.842

Molecular and Cellular Biochemistry

Abstract:Activation of hepatic stellate cells from quiescence to myofibroblast-like cells (MFBs) is a pivotal event in hepatic fibrogenesis. Plastic-cultured stellate cells (an established in vitro model of the activated phenotype) recultured on Matrigel revert to quiescence. In the present study we analyzed the molecular mechanism underlying this process, focusing on the effect of collagen receptors alpha(2)beta(1) and alpha(1)beta(1) integrin signaling on the expression of Ets-1 transcription factor and its target gene MMP1 in cultured human MFBs. Cells grown in 3-dimensional (3D) substrates (Matrigel) or collagen type I gel) markedly upregulated Ets-1 and MMP1 messages, in comparison to cells cultured on plastic. A similar effect but less intense was mimicked by stimulation of alpha(2)beta(1) or blocking of alpha(1)beta(1) integrin in cells grown on plastic. We observed increased expression of MMP1 transcripts with parallel changes in MMP1 promoter activity, and in mRNA and protein levels of upstream transcription factors Ets-1 and c-Jun. Interference with alpha(2)beta(1) and alpha(1)beta(1) integrin function in cells cultured in a 3D collagen substrate resulted in an even greater effect. Morphologically, stimulation of alpha(2)beta(1) integrin resulted in formation of multicellular networks, probably by facilitation of cell migration. Thus, we report the novel observation that in cultured human MFBs reverting to quiescence, the expression of transcription factor Ets-1 and its downstream target MMP1 can be modulated by changes in the microenvironment, which are mediated, at least in part, by the balance between collagen receptor integrin alpha(2)beta(1) and alpha(1)beta(1) activities.
Future of brain stimulation: New targets, new indications, new technology

Marwan Hariz,Patric Blomstedt,Ludvic Zrinzo

DOI: https://doi.org/10.1002/mds.25665

IF: 9.698

2013-10-07

Movement Disorders

Abstract:In the last quarter of a century, DBS has become an established neurosurgical treatment for Parkinson's disease (PD), dystonia, and tremors. Improved understanding of brain circuitries and their involvement in various neurological and psychiatric illnesses, coupled with the safety of DBS and its exquisite role as a tool for ethical study of the human brain, have unlocked new opportunities for this technology, both for future therapies and in research. Serendipitous discoveries and advances in structural and functional imaging are providing abundant "new" brain targets for an ever-increasing number of pathologies, leading to investigations of DBS in diverse neurological, psychiatric, behavioral, and cognitive conditions. Trials and "proof of concept" studies of DBS are underway in pain, epilepsy, tinnitus, OCD, depression, and Gilles de la Tourette syndrome, as well as in eating disorders, addiction, cognitive decline, consciousness, and autonomic states. In parallel, ongoing technological development will provide pulse generators with longer battery longevity, segmental electrode designs allowing a current steering, and the possibility to deliver "on-demand" stimulation based on closed-loop concepts. The future of brain stimulation is certainly promising, especially for movement disorders-that will remain the main indication for DBS for the foreseeable future-and probably for some psychiatric disorders. However, brain stimulation as a technique may be at risk of gliding down a slippery slope: Some reports indicate a disturbing trend with suggestions that future DBS may be proposed for enhancement of memory in healthy people, or as a tool for "treatment" of "antisocial behavior" and for improving "morality."

clinical neurology
[Networkmodulation through deep brain stimulation]

V Visser-Vandewalle

Abstract:Background: Deep brain stimulation (DBS) is widely performed since 1987, mainly in the realm of movement disorders. Aim: To provide an overview of the current state of DBS in various neuropsychiatric disorders and to provide an overview of new developments. Method: Narrative review of recent literature. Results: Several studies have shown the potential of DBS for carefully selected patients suffering from refractory neuropsychiatic indications such as Tourette syndrome, obsessive-compulsive disorder, depression, and Alzheimer’s disease. Applying for a CE or FDA approval by the implant manufacturer by means of double-blinded controlled trials has become highly cumbersome because of the new stricter European medical device regulation. For these RCTs to be successful, a sufficiently long follow-up time and the neurosurgeon’s knowledge of the most optimal stimulation point are required. The latest technical advances focussing on network stimulation have greatly added to defining this optimal stimulation point per disease. Conclusion: DBS is a safe technique with a proven effect on more than 200,000 patients with movement disorders. Trials into the application of DBS for the most important psychiatric and cognitive indications are important.
Advances in The Development of New Stimulation Paradigms of Deep Brain Stimulation

Wang Zhao-Xiang,Feng Zhou-Yan,Yang Gang-Sheng,Zheng Lu-Piao

DOI: https://doi.org/10.16476/j.pibb.2020.0212

2021-01-01

PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS

Abstract:Deep brain stimulation (DBS) has become one of the common treatments for movement disorders such as Parkinson's disease. It is also a promising treatment for other neurological and psychiatric disorders. However, the stimulation paradigms of regular DBS are not diversified enough to meet the needs for extending its applications, because current DBS therapy usually utilizes single-channel high-frequency stimulation of electrical pulses with a constant inter-pulse-interval. According to the desynchronization mechanisms of DBS, new stimulation paradigms have been developed by designing the temporal and spatial patterns of pulse sequences to improve the therapeutic efficacy, to extend its application and to save the electric energy of impulse generator. The new paradigms include: stimulations of varying-frequency sequences (including regular varying-frequency and random varying-frequency), multi-channel asynchronous stimulations at different spatial locations, as well as the combined stimulations of varying-frequency and multi-channels. These new paradigms may improve the efficacy of DBS and reduce the energy consumption thereby showing good prospects in treating Parkinson's disease and other brain diseases such as epilepsy, obsessive-compulsive and minimally conscious state. Notably, in addition to the better acute effect during the stimulations, the efficacy of multi-channel stimulations may last for a long time after the termination of stimulations, indicating a sustained effect or an after-effect. This performance breaks the limitation of regular DBS that has only acute effects and opens out a new prospect for DBS. Based on a summary of the stimulation paradigms of regular DBS and their underlying mechanisms, this review presents the development of new DBS paradigms on the stimulations of varying-frequency and multi-channels to generate asynchronous effects, thereby providing valuable information for the development of DBS.
Perspectives of Implementation of Closed-Loop Deep Brain Stimulation: From Neurological to Psychiatric Disorders

Sergiu Groppa,Gabriel Gonzalez-Escamilla,Gerd Tinkhauser,Halim Ibrahim Baqapuri,Bastian Sajonz,Christoph Wiest,Joana Pereira,Damian M Herz,Matthias R Dold,Manuel Bange,Dumitru Ciolac,Viviane Almeida,John Neuber,Daniela Mirzac,Juan Francisco Martín-Rodríguez,Christian Dresel,Muthuraman Muthuraman,Astrid D Adarmes Gomez,Marta Navas,Gizem Temiz,Aysegul Gunduz,Lilia Rotaru,Yaroslav Winter,Rick Schuurman,Maria F Contarino,Martin Glaser,Michael Tangermann,Albert F G Leentjens,Pablo Mir,Cristina V Torres Diaz,Carine Karachi,David E J Linden,Huiling Tan,Volker A Coenen,Damian M. Herz,Matthias R. Dold,Astrid D. Adarmes Gomez,Maria F. Contarino,Albert F.G. Leentjens,Cristina V. Torres Diaz,David E.J. Linden,Volker A. Coenen,

DOI: https://doi.org/10.1159/000535114

IF: 1.643

2023-12-12

Stereotactic and Functional Neurosurgery

Abstract:Background: Deep brain stimulation (DBS) is a highly efficient, evidence-based therapy to alleviate symptoms and improve quality of life in movement disorders such as Parkinson’s disease, essential tremor, and dystonia, which is also being applied in several psychiatric disorders, such as obsessive-compulsive disorder and depression, when they are otherwise resistant to therapy. Summary: At present, DBS is clinically applied in the so-called open-loop approach, with fixed stimulation parameters, irrespective of the patients’ clinical state(s). This approach ignores the brain states or feedback from the central nervous system or peripheral recordings, thus potentially limiting its efficacy and inducing side effects by stimulation of the targeted networks below or above the therapeutic level. Key Messages: The currently emerging closed-loop (CL) approaches are designed to adapt stimulation parameters to the electrophysiological surrogates of disease symptoms and states. CL-DBS paves the way for adaptive personalized DBS protocols. This review elaborates on the perspectives of the CL technology and discusses its opportunities as well as its potential pitfalls for both clinical and research use in neuropsychiatric disorders.

surgery,neurosciences,neuroimaging
The Present Indication and Future of Deep Brain Stimulation

Kenji SUGIYAMA,Takao NOZAKI,Tetsuya ASAKAWA,Shinichiro KOIZUMI,Osamu SAITOH,Hiroki NAMBA

DOI: https://doi.org/10.2176/nmc.ra.2014-0394

2015-01-01

Abstract:The use of electrical stimulation to treat pain in human disease dates back to ancient Rome or Greece. Modern deep brain stimulation (DBS) was initially applied for pain treatment in the 1960s, and was later used to treat movement disorders in the 1990s. After recognition of DBS as a therapy for central nervous system (CNS) circuit disorders, DBS use showed drastic increase in terms of adaptability to disease and the patient's population. More than 100,000 patients have received DBS therapy worldwide. The established indications for DBS are Parkinson's disease, tremor, and dystonia, whereas global indications of DBS expanded to other neuronal diseases or disorders such as neuropathic pain, epilepsy, and tinnitus. DBS is also experimentally used to manage cognitive disorders and psychiatric diseases such as major depression, obsessive-compulsive disorder (OCD), Tourette's syndrome, and eating disorders. The importance of ethics and conflicts surrounding the regulation and freedom of choice associated with the application of DBS therapy for new diseases or disorders is increasing. These debates are centered on the use of DBS to treat new diseases and disorders as well as its potential to enhance ability in normal healthy individuals. Here we present three issues that need to be addressed in the future: (1) elucidation of the mechanisms of DBS, (2) development of new DBS methods, and (3) miniaturization of the DBS system. With the use of DBS, functional neurosurgery entered into the new era that man can manage and control the brain circuit to treat intractable neuronal diseases and disorders.

surgery,clinical neurology
Proceedings of the Eighth Annual Deep Brain Stimulation Think Tank: Advances in Optogenetics, Ethical Issues Affecting DBS Research, Neuromodulatory Approaches for Depression, Adaptive Neurostimulation, and Emerging DBS Technologies

Vinata Vedam-Mai,Karl Deisseroth,James Giordano,Gabriel Lazaro-Munoz,Winston Chiong,Nanthia Suthana,Jean-Philippe Langevin,Jay Gill,Wayne Goodman,Nicole R. Provenza,Casey H. Halpern,Rajat S. Shivacharan,Tricia N. Cunningham,Sameer A. Sheth,Nader Pouratian,Katherine W. Scangos,Helen S. Mayberg,Andreas Horn,Kara A. Johnson,Christopher R. Butson,Ro’ee Gilron,Coralie de Hemptinne,Robert Wilt,Maria Yaroshinsky,Simon Little,Philip Starr,Greg Worrell,Prasad Shirvalkar,Edward Chang,Jens Volkmann,Muthuraman Muthuraman,Sergiu Groppa,Andrea A. Kühn,Luming Li,Matthew Johnson,Kevin J. Otto,Robert Raike,Steve Goetz,Chengyuan Wu,Peter Silburn,Binith Cheeran,Yagna J. Pathak,Mahsa Malekmohammadi,Aysegul Gunduz,Joshua K. Wong,Stephanie Cernera,Wei Hu,Aparna Wagle Shukla,Adolfo Ramirez-Zamora,Wissam Deeb,Addie Patterson,Kelly D. Foote,Michael S. Okun

DOI: https://doi.org/10.3389/fnhum.2021.644593

IF: 3.473

2021-04-19

Frontiers in Human Neuroscience

Abstract:We estimate that 208,000 deep brain stimulation (DBS) devices have been implanted to address neurological and neuropsychiatric disorders worldwide. DBS Think Tank presenters pooled data and determined that DBS expanded in its scope and has been applied to multiple brain disorders in an effort to modulate neural circuitry. The DBS Think Tank was founded in 2012 providing a space where clinicians, engineers, researchers from industry and academia discuss current and emerging DBS technologies and logistical and ethical issues facing the field. The emphasis is on cutting edge research and collaboration aimed to advance the DBS field. The Eighth Annual DBS Think Tank was held virtually on September 1 and 2, 2020 (Zoom Video Communications) due to restrictions related to the COVID-19 pandemic. The meeting focused on advances in: (1) optogenetics as a tool for comprehending neurobiology of diseases and on optogenetically-inspired DBS, (2) cutting edge of emerging DBS technologies, (3) ethical issues affecting DBS research and access to care, (4) neuromodulatory approaches for depression, (5) advancing novel hardware, software and imaging methodologies, (6) use of neurophysiological signals in adaptive neurostimulation, and (7) use of more advanced technologies to improve DBS clinical outcomes. There were 178 attendees who participated in a DBS Think Tank survey, which revealed the expansion of DBS into several indications such as obesity, post-traumatic stress disorder, addiction and Alzheimer’s disease. This proceedings summarizes the advances discussed at the Eighth Annual DBS Think Tank.

psychology,neurosciences
Deep brain stimulation of the subthalamic nucleus in Parkinson disease 2013–2023: where are we a further 10 years on?

Andrew Brian O’Keeffe,Anca Merla,Keyoumars Ashkan

DOI: https://doi.org/10.1080/02688697.2024.2311128

2024-02-09

British Journal of Neurosurgery

Abstract:Deep brain stimulation has been in clinical use for 30 years and during that time it has changed markedly from a small-scale treatment employed by only a few highly specialized centers into a widespread keystone approach to the management of disorders such as Parkinson's disease. In the intervening decades, many of the broad principles of deep brain stimulation have remained unchanged, that of electrode insertion into stereotactically targeted brain nuclei, however the underlying technology and understanding around the approach have progressed markedly. Some of the most significant advances have taken place over the last decade with the advent of artificial intelligence, directional electrodes, stimulation/recording implantable pulse generators and the potential for remote programming among many other innovations. New therapeutic targets are being assessed for their potential benefits and a surge in the number of deep brain stimulation implantations has given birth to a flourishing scientific literature surrounding the pathophysiology of brain disorders such as Parkinson's disease. Here we outline the developments of the last decade and look to the future of deep brain stimulation to attempt to discern some of the most promising lines of inquiry in this fast-paced and rapidly evolving field.

surgery,clinical neurology
Probing responses to deep brain stimulation with functional magnetic resonance imaging

Aaron Loh,David Gwun,Clement T Chow,Alexandre Boutet,Jordy Tasserie,Jürgen Germann,Brendan Santyr,Gavin Elias,Kazuaki Yamamoto,Can Sarica,Artur Vetkas,Ajmal Zemmar,Radhika Madhavan,Alfonso Fasano,Andres M Lozano

DOI: https://doi.org/10.1016/j.brs.2022.03.009

Abstract:Background: Deep brain stimulation (DBS) is an established treatment for certain movement disorders and has additionally shown promise for various psychiatric, cognitive, and seizure disorders. However, the mechanisms through which stimulation exerts therapeutic effects are incompletely understood. A technique that may help to address this knowledge gap is functional magnetic resonance imaging (fMRI). This is a non-invasive imaging tool which permits the observation of DBS effects in vivo. Objective: The objective of this review was to provide a comprehensive overview of studies in which fMRI during active DBS was performed, including studied disorders, stimulated brain regions, experimental designs, and the insights gleaned from stimulation-evoked fMRI responses. Methods: We conducted a systematic review of published human studies in which fMRI was performed during active stimulation in DBS patients. The search was conducted using PubMED and MEDLINE. Results: The rate of fMRI DBS studies is increasing over time, with 37 studies identified overall. The median number of DBS patients per study was 10 (range = 1-67, interquartile range = 11). Studies examined fMRI responses in various disease cohorts, including Parkinson's disease (24 studies), essential tremor (3 studies), epilepsy (3 studies), obsessive-compulsive disorder (2 studies), pain (2 studies), Tourette syndrome (1 study), major depressive disorder, anorexia, and bipolar disorder (1 study), and dementia with Lewy bodies (1 study). The most commonly stimulated brain region was the subthalamic nucleus (24 studies). Studies showed that DBS modulates large-scale brain networks, and that stimulation-evoked fMRI responses are related to the site of stimulation, stimulation parameters, patient characteristics, and therapeutic outcomes. Finally, a number of studies proposed fMRI-based biomarkers for DBS treatment, highlighting ways in which fMRI could be used to confirm circuit engagement and refine DBS therapy. Conclusion: A review of the literature reflects an exciting and expanding field, showing that the combination of DBS and fMRI represents a uniquely powerful tool for simultaneously manipulating and observing neural circuitry. Future work should focus on relatively understudied disease cohorts and stimulated regions, while focusing on the prospective validation of putative fMRI-based biomarkers.
Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology

Adolfo Ramirez-Zamora,James Giordano,Aysegul Gunduz,Jose Alcantara,Jackson N. Cagle,Stephanie Cernera,Parker Difuntorum,Robert S. Eisinger,Julieth Gomez,Sarah Long,Brandon Parks,Joshua K. Wong,Shannon Chiu,Bhavana Patel,Warren M. Grill,Harrison C. Walker,Simon J. Little,Ro’ee Gilron,Gerd Tinkhauser,Wesley Thevathasan,Nicholas C. Sinclair,Andres M. Lozano,Thomas Foltynie,Alfonso Fasano,Sameer A. Sheth,Katherine Scangos,Terence D. Sanger,Jonathan Miller,Audrey C. Brumback,Priya Rajasethupathy,Cameron McIntyre,Leslie Schlachter,Nanthia Suthana,Cynthia Kubu,Lauren R. Sankary,Karen Herrera-Ferrá,Steven Goetz,Binith Cheeran,G. Karl Steinke,Christopher Hess,Leonardo Almeida,Wissam Deeb,Kelly D. Foote,Michael S. Okun

DOI: https://doi.org/10.3389/fnhum.2020.00054

IF: 3.473

2020-03-27

Frontiers in Human Neuroscience

Abstract:The Seventh Annual Deep Brain Stimulation (DBS) Think Tank held on September 8th of 2019 addressed the most current: (1) use and utility of complex neurophysiological signals for development of adaptive neurostimulation to improve clinical outcomes; (2) Advancements in recent neuromodulation techniques to treat neuropsychiatric disorders; (3) New developments in optogenetics and DBS; (4) The use of augmented Virtual reality (VR) and neuromodulation; (5) commercially available technologies; and (6) ethical issues arising in and from research and use of DBS. These advances serve as both "markers of progress" and challenges and opportunities for ongoing address, engagement, and deliberation as we move to improve the functional capabilities and translational value of DBS. It is in this light that these proceedings are presented to inform the field and initiate ongoing discourse. As consistent with the intent, and spirit of this, and prior DBS Think Tanks, the overarching goal is to continue to develop multidisciplinary collaborations to rapidly advance the field and ultimately improve patient outcomes.

psychology,neurosciences
Proceedings of the Sixth Deep Brain Stimulation Think Tank Modulation of Brain Networks and Application of Advanced Neuroimaging, Neurophysiology, and Optogenetics

Adolfo Ramirez-Zamora,James Giordano,Edward S. Boyden,Viviana Gradinaru,Aysegul Gunduz,Philip A. Starr,Sameer A. Sheth,Cameron C. McIntyre,Michael D. Fox,Jerrold Vitek,Vinata Vedam-Mai,Umer Akbar,Leonardo Almeida,Helen M. Bronte-Stewart,Helen S. Mayberg,Nader Pouratian,Aryn H. Gittis,Annabelle C. Singer,Meaghan C. Creed,Gabriel Lazaro-Munoz,Mark Richardson,Marvin A. Rossi,Leopoldo Cendejas-Zaragoza,Pierre-Francois D’Haese,Winston Chiong,Ro’ee Gilron,Howard Chizeck,Andrew Ko,Kenneth B. Baker,Joost Wagenaar,Noam Harel,Wissam Deeb,Kelly D. Foote,Michael S. Okun

DOI: https://doi.org/10.3389/fnins.2019.00936

IF: 4.3

2019-09-12

Frontiers in Neuroscience

Abstract:The annual deep brain stimulation (DBS) Think Tank aims to create an opportunity for a multidisciplinary discussion in the field of neuromodulation to examine developments, opportunities and challenges in the field. The proceedings of the Sixth Annual Think Tank recapitulate progress in applications of neurotechnology, neurophysiology, and emerging techniques for the treatment of a range of psychiatric and neurological conditions including Parkinson's disease, essential tremor, Tourette syndrome, epilepsy, cognitive disorders, and addiction. Each section of this overview provides insight about the understanding of neuromodulation for specific disease and discusses current challenges and future directions. This year's report addresses key issues in implementing advanced neurophysiological techniques, evolving use of novel modulation techniques to deliver DBS, ans improved neuroimaging techniques. The proceedings also offer insights into the new era of brain network neuromodulation and connectomic DBS to define and target dysfunctional brain networks. The proceedings also focused on innovations in applications and understanding of adaptive DBS (closed-loop systems), the use and applications of optogenetics in the field of neurostimulation and the need to develop databases for DBS indications. Finally, updates on neuroethical, legal, social, and policy issues relevant to DBS research are discussed.

neurosciences

[Pseudotumoral osseous change of the sternum during chronic leukemia in an adult].

Technology of deep brain stimulation: current status and future directions

Ketoconazole Inhibits the Growth and Development of Ichthyophonus sp. (Mesomycetozoa) In Vitro

Deep Brain Stimulation Initiative: Toward Innovative Technology, New Disease Indications, And Approaches To Current And Future Clinical Challenges In Neuromodulation Therapy

Current and future directions of deep brain stimulation for neurological and psychiatric disorders

Current Practice and the Future of Deep Brain Stimulation Therapy in Parkinson's Disease

Advances in Understanding The Mechanisms of Deep Brain Stimulation

Deep Brain Stimulation Programming 2.0: Future Perspectives for Target Identification and Adaptive Closed Loop Stimulation

Deep Brain Stimulation beyond the Clinic: Navigating the Future of Parkinson’s and Alzheimer’s Disease Therapy

The mechanisms of action of deep brain stimulation and ideas for the future development

Collagen binding alpha2beta1 and alpha1beta1 integrins play contrasting roles in regulation of Ets-1 expression in human liver myofibroblasts.

Future of brain stimulation: New targets, new indications, new technology

[Networkmodulation through deep brain stimulation]

Advances in The Development of New Stimulation Paradigms of Deep Brain Stimulation

Perspectives of Implementation of Closed-Loop Deep Brain Stimulation: From Neurological to Psychiatric Disorders

The Present Indication and Future of Deep Brain Stimulation

Proceedings of the Eighth Annual Deep Brain Stimulation Think Tank: Advances in Optogenetics, Ethical Issues Affecting DBS Research, Neuromodulatory Approaches for Depression, Adaptive Neurostimulation, and Emerging DBS Technologies

Deep brain stimulation of the subthalamic nucleus in Parkinson disease 2013–2023: where are we a further 10 years on?

Probing responses to deep brain stimulation with functional magnetic resonance imaging

Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology

Proceedings of the Sixth Deep Brain Stimulation Think Tank Modulation of Brain Networks and Application of Advanced Neuroimaging, Neurophysiology, and Optogenetics